Improving the safety of high-dose methotrexate for children with hematologic cancers in settings without access to MTX levels using extended hydration and additional leucovorin.
Kalthi VaishnaviDeepak BansalAmita TrehanRicha JainSavita Verma AttriPublished in: Pediatric blood & cancer (2018)
It is safe to administer 3 or 5 gm/m2 of MTX (24 hr infusion) without measuring MTX levels, with extended hydration, additional doses of leucovorin, and monitoring of serum creatinine and urine pH.